BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27716842)

  • 1. Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical Prostatectomy.
    Jang WS; Kim LH; Yoon CY; Rha KH; Choi YD; Hong SJ; Ham WS
    PLoS One; 2016; 11(10):e0164497. PubMed ID: 27716842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of adverse pathologic features after radical prostatectomy in low-risk prostate cancer.
    Park JW; Koh DH; Jang WS; Cho KS; Ham WS; Rha KH; Hong SJ; Choi YD
    BMC Cancer; 2018 May; 18(1):545. PubMed ID: 29743042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
    Badani KK; Reddy BN; Moskowitz EJ; Paulucci DJ; Beksac AT; Martini A; Whalen MJ; Skarecky DW; Huynh LM; Ahlering TE
    Urol Oncol; 2018 Jun; 36(6):310.e1-310.e6. PubMed ID: 29625782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
    Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
    Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
    Merriman KM; Harmon SA; Belue MJ; Yilmaz EC; Blake Z; Lay NS; Phelps TE; Merino MJ; Parnes HL; Law YM; Gurram S; Wood BJ; Choyke PL; Pinto PA; Turkbey B
    AJR Am J Roentgenol; 2023 Dec; 221(6):773-787. PubMed ID: 37404084
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?
    Simon RM; Howard LE; Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Vidal AC
    BJU Int; 2016 Jun; 117(6):897-903. PubMed ID: 26010251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
    Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
    BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between Seminal Vesicle Invasion and Prostate Cancer Detection Location after Transrectal Systemic Biopsy among Men Who Underwent Radical Prostatectomy.
    Lee YI; Lee HM; Jo JK; Lee S; Hong SK; Byun SS; Lee SE; Oh JJ
    PLoS One; 2016; 11(2):e0148690. PubMed ID: 26848747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.
    Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA
    J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8.
    Manoharan M; Bird VG; Kim SS; Civantos F; Soloway MS
    BJU Int; 2003 Oct; 92(6):539-44. PubMed ID: 14511029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of surgical margin status on prostate-cancer-specific mortality.
    Chalfin HJ; Dinizo M; Trock BJ; Feng Z; Partin AW; Walsh PC; Humphreys E; Han M
    BJU Int; 2012 Dec; 110(11):1684-9. PubMed ID: 22788795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.
    Imnadze M; Sjoberg DD; Vickers AJ
    Eur Urol; 2016 Jan; 69(1):143-8. PubMed ID: 25913389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.
    Hegde JV; Veruttipong D; Said JW; Reiter RE; Steinberg ML; King CR; Kishan AU
    Urology; 2017 Sep; 107():171-177. PubMed ID: 28552819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Gleason score on biochemical recurrence in patients with pT3aN0/Nx prostate cancer with positive surgical margins: a multicenter study from the Prostate Cancer Research Committee.
    Song W; Lee DH; Jeon HG; Jeong BC; Seo SI; Lee HM; Choi HY; Kim JW; Lee S; Byun SS; Jeong CW; Kwak C; Cho JS; Ahn H; Jeon SS
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2393-2400. PubMed ID: 28823006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
    Heering M; Berg KD; Brasso K; Iversen P; Røder MA
    Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy.
    Pagano MJ; Whalen MJ; Paulucci DJ; Reddy BN; Matulay JT; Rothberg M; Scarberry K; Patel T; Shapiro EY; RoyChoudhury A; McKiernan J; Benson MC; Badani KK
    Prostate; 2016 Feb; 76(2):226-34. PubMed ID: 26481325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
    Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
    Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.